MindImmune Therapeutics Inc.

MindImmune is a drug discovery venture focused on neuroinflammation, targeting Alzheimer’s as lead indication.The company is in a vanguard of next generation drug developers aiming to modulate the immune system in treating brain disease. Founded by a team of experienced CNS researchers who first collaborated while at Pfizer, the company has developed a platform for inhibiting dendritic cell recruitment triggered as part of the innate immune response to pathology in the brain. MindImmune has recently identified a therapeutic antibody which blocks dendritic cell recruitment from the periphery into the brain. In so doing, the company has demonstrated that the synaptic damage that leads to cognitive impairment can be rapidly arrested. The company launched in 2016 in collaboration with the Ryan Institute for Neuroscience at the University of Rhode Island. Investors include Pfizer Ventures and H. Lundbeck A/S.